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Site-directed mutagenesisThe important role that extracellular adenosine plays in many physiological processes is mediated by the
adenosine class of G protein-coupled receptors, a class of receptors that also responds to the antagonist caffeine,
themost widely used pharmacological agent in theworld. The crystallographic model of the human adenosine
A2A receptorwas recently solved to 2.6 Å in complexwith the antagonist ZM241385,which is also referred to as
“super-caffeine” because of its strong antagonistic effect on adenosine receptors. The crystallographic model
revealed some unexpected and unusual features of the adenosine A2A receptor structure that have led to new
studies on the receptor and the re-examination of pre-existing data. Compared to other known GPCR
structures, the adenosine A2A receptor has a unique ligand binding pocket that is nearly perpendicular to the
membrane plane. The ligand binding site highlights the integral role of the helical core together with the
extracellular loops and the four disulﬁde bridges in the extracellular domain, in ligand recognition by the
adenosine class of GPCRs. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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There are four subtypes of adenosine receptor – adenosine A1, A2A,
A2B and A3 – all of which are members of the heterotrimeric guanine
nucleotide-binding protein (G protein) coupled receptor (GPCR)family A (Table 1). Each receptor subtype has a unique ligand binding
proﬁle, activation proﬁle, subcellular localization and G protein
binding preference (reviewed extensively elsewhere in this special
issue on adenosine receptors).
The adenosine A1 and A2A receptor subtypes modulate neuronal
activity by regulating neurotransmitter release and depolarization both
presynaptically (adenosine A1 receptor) and postsynaptically (adeno-
sine A2A receptor) in speciﬁc cell types throughout the central and
peripheral nervous system. They are implicated in a number of
neurological diseases including Alzheimer's disease, Parkinson's
Table 1
Primary sequence and key properties of human adenosine receptors.
Subtype Pubmed
symbol
PID ID #
(PDB ID #)
Chromosomal
location
G protein
coupling
Predicted MW
(by amino acid
sequence) [Da]
Length
[Residues]
# of potential
glycosylation sites
Predicted
pI
Predicted phosphorylation
Server 1a Server 2b
A1 ADORA1 P30542.1 (−) 1q32.1 i/o 36,512 326 1 8.9 - Ser176/261/218/219;
Thr78/120; Tyr106
A2A ADORA2A P29274.2 (3EML) 22q11.2 s, olf 44,707 412 1 8.34 Thr298 Ser156/223/374/387;
Thr224/298/319
A2B ADORA2B P29275.1 (−) 17p12-p11.2 s, q 36,333 332 2 8.62 Tyr113 Ser115/149/283;
Thr40/161/225;
Tyr10/229
A3 ADORA3 P33765.2 (−) 1p13.2 i/o 36,185 318 3 9.11 Ser317; Pro305,
Asn316
Ser215/275/317;
Thr122/123/228/312;
Tyr15/109/293
a www.phosphosite.org.
b http://www.cbs.dtu.dk/services/NetPhos/.
Table 2
The percentage of residues that match exactly (identical residues) between the two
sequences. The amino acid sequences were aligned using the TCoffee (www.tcoffee.org)
and GeneDoc (http://www.nrbsc.org/gfx/genedoc) programs.
Adenosine receptor
subtype (PID ID #)
A1
(P30542.1)
A2A
(P29274.2)
A2B
(P29275.1)
A3
(P33765.2)
A1 (P30542.1) 37% 42% 46%
A2A (P29274.2) 46% 31%
A2B (P29275.1) 35%
A3 (P33765.2)
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ton's disease and multiple sclerosis, as well as the brain damage
associated with stroke, and have been pursued as therapeutic targets to
treat these diseases as well as insomnia, pain and drug addiction [1]. In
non-neuronal tissues the adenosine A2A receptor is also involved in
inﬂammation and regulation of myocardial oxygen consumption and
coronary blood ﬂow, and the United States Food and Drug Administra-
tion recently approved the adenosineA2A receptor agonist Regadenoson
(CTV-3146, LexiscanTM) as a coronary vasodilator for use in myocardial
perfusion imaging [2].
Activity of the adenosine A1, A2A, and A2B receptor subtypes is
inhibited by naturally occurring methylxanthines such as caffeine or
theophylline [3]. Recent epidemiological studies suggest that coffee
and tea consumers have a lower risk of Parkinson's disease [4], an
effect that has been linked to the blockade of the adenosine A2A
receptor subtype by caffeine as the adenosine A2A receptor controls
locomotor behaviour and neurotransmitter release in basal ganglia
[5,6]. Furthermore, it has recently been observed that the non-
xanthine synthetic adenosine A2A receptor antagonist ZM241385, a
triazolotriazine, enhanced L-DOPA derived dopamine release [7,8].
Not surprisingly, many drug discovery teams have developed
antagonists for the adenosine A2A receptor as potential therapeutic
agents to control the impairment of motor skills that occurs in
Parkinson's disease.
In this review we summarize the main structural features of the
human adenosine A2A receptor:ZM241385 complex, and compare the
main similarities and differences of this structure to other solved
GPCR structures.
2. Primary sequence and covalent modiﬁcations of
adenosine receptors
The overall sequence similarity between human adenosine
receptors is relatively high (Table 2). The adenosine A2A receptor
has higher sequence identity to the adenosine A2B receptor (46%) than
to either the adenosine A1 (37%) or A3 (31%) receptors. All subtypes
have potential N-linked glycosylation sites, and the adenosine A1, A2B
and A3 receptor subtypes have potential palmitoylation sites at the
end of helix 8 that are lacking in the adenosine A2A receptor (Table 1
and Fig. 1; Arg309(8.60)). Glycosylation(s) state does not alter ligand
binding properties but may be important in targeting receptors to the
plasma membrane. Removal of palmitoylation sites by mutagenesis
had no effect on binding to G protein or receptor down-regulation but
did affect receptor degradation after synthesis [9,10]. In contrast to
the adenosine A1 receptor, depalmitoylation of the adenosine A3
receptor increases phosphorylation of the receptor by GPCR kinases
(GRKs) causing rapid desensitization of the receptor [9–11]. There areseveral predicted phosphorylation sites in both the cytoplasmic and
carboxy terminal domains of all four adenosine receptor subtypes
Table 1.3. Overall three-dimensional structure and comparison to
other GPCRs
High-resolution crystallographic entries in the protein data bank
are available for four unique GPCRs: human adenosine A2A receptor
(one entry; with ZM241385 bound), turkey β1-adrenoceptor (one
entry; with cyanopindolol), human β2-adrenoceptor (ﬁve entries;
with carazolol and timolol bound) and bovine/squid rhodopsin/opsin
(14 entries; with and without retinal) (www.pdb.org/). All of these
receptors have seven transmembrane α-helices (7TM, helices 1–7)
followed by one short membrane-associated helix (helix 8), an
extracellular amino-terminus (N-terminus), a cytosolic carboxy
terminus (C-terminus), three extracellular loops (ECL1-3) and three
intracellular loops (ICL1-3, Fig. 2). Although the primary sequence
variation within GPCR family A members is quite large and only a few
residues in the transmembrane domains are highly conserved (Fig. 2,
Ballesteros–Weinstein residues and so-called microdomains, see
section 4.1), the overall structure of the 7TM domain is very similar
among all the solved GPCR structures, and differs considerably from
the bacterial counterparts such as bacteriorhodopsin ground-state
and the photocycle intermediate structures halorhodopsin and
sensory rhodopsin [12]. The helical domain of the adenosine A2A
receptor can be superimposed over the same domain in the other
solved GPCR structures with an r.m.s.d. b 2.6 Å (c-alpha) (Table 3).
The r.m.s.d. decreases to ∼1.2 Å if only the most conserved residues
within these structures are selected (97 residues), indicating that all
these GPCRs possess very similar arrangements of their 7TM domains
[13]. In contrast, the structures of bacterial rhodopsin and the solved
GPCRs do not align very well (Table 3). Despite the high structural
1235H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244similarity among GPCR transmembrane domains, the extramembrane
domains show signiﬁcant structural diversity.4. Heptahelical microdomains in GPCRs
The most conserved residues and sequence motifs among GPCR
family A members can be classiﬁed as microdomains. These micro-
domains include: i) the most conserved residues in the transmem-
brane helices, ii) the DR(3.50)Y-motif, iii) the rotamer toggle residues,
iv) the NP(7.50)XXY(X)5,6F-motif and v) Cys-bridge between helix 3
and ECL2.4.1. The most conserved residues among family A GPCRs
The most conserved helical residues among family A GPCRs are
usually referred to as Ballesteros–Weinstein residues and indexed by
the numbering system proposed by Ballesteros and Weinstein [14].
Transmembrane helices V, VI and VII have conserved proline residues
in the helix. These residues are indexed as X.50, where X is the
transmembrane helix number (5–7). Other residues in the same
transmembrane helix are indexed relative to the.50 reference
number.
Interestingly, the conserved proline residue is typically located in
the middle of the transmembrane helix, and the conformation of the
proline residue causes bending, irregularities (phi-helical and 3(10)
conformations) and broken hydrogen bonds in the alpha helix.
Because of the high conservation of this residue, it is possible that the
strong effects that this mid-helix proline has on helix structure are
relevant and important for the conformational changes that the family
A GPCRs undergo during activation.Fig. 1. Three-dimensional structure of human adenosine A2A receptor:antagonist ZM241385
cartoon diagram (N-terminus, blue; C-terminus, red). The T4 lysozyme fusion protein doma
phar.umich.edu/ andmarked as grey coloured “dummy” atoms. Bound ZM241385 (pink) and
representation of the hydrogen bonding and aromatic interactions between the receptor an4.2. “Ionic lock” and DR(3.50)Y-motif
The “ionic lock” and DR(3.50)Y-motif (and its extension D[E]RY
[W]) are highly conserved (N65%) among family A GPCRs, and likely
play a role in controlling the activity of the receptor. Rhodopsin in its
inactive state exhibits very low basal activity in the dark, which is
essential for proper vision. In the structure of bovine rhodopsin in its
inactive state, Arg(3.50) of helix 3 makes salt bridges with the equally
conserved Glu(6.30) of helix 6 and Glu(3.49) of helix 3. This
arrangement is referred to as the “ionic lock,” and is proposed to
play an important role in mainting rhodopsin in the fully inactive
conformation. Electron paramagnetic resonance (EPR) and other
biophysical methods show that when bound to a short, G protein-
mimicking peptide, helices 3 and 6 in the bovine opsin structure are
farther apart than in the unbound structure, resulting in disruption of
the salt bridge between Arg(3.50), Glu(6.30) and Glu(3.49) [15–19].
In the human adenosine A2A receptor and the β1-adrenoceptor
structures, the conserved residues that correspond to the “ionic lock”
are arranged differently than in the other GPCR family members
solved to date. In the high afﬁnity antagonist-occupied structures of
adenosine A2A receptor (ZM241385) and turkey β1-adrenoceptor
(cyanopindolol), Asp(3.49) from the DR(3.50)Y motif interacts with
the tyrosine (Tyr3.60) residue from ICL2 instead of Glu(6.30) from
helix 6, and constrains the helical conformation of ICL2 (Fig. 3B).
Although the human β2-adrenoceptor has the same sequence motif
and a tyrosine at the 3.60 position of ICL2, in both the timolol and
carazolol occupied structures, Asp130(3.49) interacts with Ser143
(3.62), and the short helical motif found in ICL2 in the adenosine A2A
receptor structure is lacking from both solved β2-adrenoceptor
structures (carazolol and timolol). Despite this lack of a stabilizing
salt bridge in the two β2-adrenoceptor structures, previous observa-
tions have suggested that an “ionic lock” stabilizes other family A GPCRcomplex (PDB ID # 3EML). A. The overall structure is represented as a rainbow coloured
in is shown in purple. The membrane boundary planes are obtained from http://opm.
lipids (black, Ste #402 – Ste #406) are shown as stick models. B. Schematic ligand-plot
d ZM241385 in the antagonist binding cavity.
Fig. 1 (continued).
1236 H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244members, including adrenoceptors [17,18]. Molecular dynamic
simulations with β2-adrenoceptor indicated the helices 3 and 6
formed an ionic lock similar to that of inactive rhodopsin. This
suggests that the β2-adrenoceptor exists in equilibrium where ionicFig. 2. A two dimensional schematic representation of human adenosine receptor subtypes. U
subtypes are shown in the green boxes. Residues which bind to the antagonist ZM241385 a
Lower panel: Extramembrane domains. Conserved residues among human adenosine rece
indicated as follows; adenosine A2A receptor residues are denoted using white square boxes,
using grey circles and adenosine A3 receptor residues using dark grey circles. All human a
residues not deﬁned in electron density are indicated in pink boxes. Cysteine residues are sho
terminal domain is excluded (Δ317–412). The lipid-bilayer boundaries are indicated as dash
subtype (PDB ID # 3EML).lock is formed or broken. Other secondary elements are also formed
during simulations including the formation of helix in ICL2 [20,21].
Three possible reasons why ionic lock is not observed in any of the
non-visual GPCRs is that the trapped crystal structures might not havepper panel: Transmembrane domains. Residues conserved in all four human adenosine
re in bold framed boxes with their corresponding Ballesteros–Weinstein indexes [14].
ptors are indicated as green boxes. The residue variation between human subtypes is
adenosine A1 receptor residues using light grey circles, adenosine A2B receptor residues
denosine A2A receptor residues have been numbered in the corresponding boxes. The
wn in yellow colour and bonds between them are in bold green dotted line. The carboxy
ed lines. The model is based on the crystal structure of human adenosine A2A receptor
1237H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244
Table 3
Overall structural similarity between the human adenosine A2A receptor (3EML) and
the presentable members of heptahelical receptors.
Receptor PDB ID #
(Chain)
Nominal
resolution [Å]
Receptor
r.m.s.d. Cα [Å]
# of Cα
aligned
H. salinarum
Bacteriorhodopsin
(proton pump)
1M0L 1.47 3.9 183
Human beta2-adrenoceptor 2RH1 2.4 1.2 166
Turkey beta1-adrenoceptor 2VT4 (A) 2.7 1.3 183
2VT4 (B) 1.4 192
2VT4 (C) 1.5 180
2VT4 (D) 1.2 182
Bovine opsin (unligated) 3CAP (A) 2.9 2.5 184
3CAP (B) 2.5 184
Bovine opsin in complex
with a C-terminal
peptide of G protein
(active or partially active)
3DQB (A) 3.2 2.6 186
Bovine rhodopsin 1U19 (A) 2.2 2.0 174
1U19 (B) 2.0 175
1238 H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244any ionic locks or themodiﬁcations required for crystallization such as
T4 lysozyme fusion, deletion of ICL3 and addition of antibody
fragment might have disrupted the ionic lock or alternatively crystal
packing forces could have overcome this interaction.
4.3. The NP(7.50)XXY(X)5,6F motif
In family A GPCRs, the conserved NP(7.50)XXY(X)5,6F sequence
motif makes several hydrogen bonds to internal water molecules
(Fig. 3A). Some of these waters are conserved among the rhodopsin,
β2-adrenoceptor and adenosine A2A receptor structures. It has been
speculated that these water molecules play an important role in the
activation process [22,23]. In the adenosine A2A receptor structure,
ordered waters form a network connecting the extracellular binding
cavity to the intracellular space (Fig. 3A).
5. Adenosine A2A receptor structure
5.1. Engineering, puriﬁcation and crystallization
The existence of multiple conformations and intrinsically disor-
dered regions in GPCRs makes them difﬁcult to crystallize. Majority of
the receptor lies in the lipid phase and this prevents the formation of
crystal contacts. Thus native receptor is unsuitable for crystallization.
The published crystal structure of the human adenosine A2A receptor
is not of the native protein but rather is of an engineered receptor, and
the successful crystallization is likely due to the introduction of these
critical changes. The engineered receptor construct is modiﬁed at the
amino-terminus by addition of a signal sequence (hemagglutinin) and
a detection tag (FLAG-M2) [24]. The hemagglutinin signal sequence
and FLAG-M2 tag as well as the ﬁrst two residues of the receptor are
not visible in the electron density maps. The carboxy terminal domain
of the engineered receptor was truncated after position Ala316
(Δ316–412), and a histidine puriﬁcation epitope (6X-His tag) was
added. C-terminal truncation removed the predicted disordered
regions and improved the likelihood of crystallogenesis. The residues
between Gln311(8.62) and Ala316(8.67) as well as the puriﬁcation
tag are not visible in the electron density map. A glycan [Asn154
(4.75)] was enzymatically removed during puriﬁcation. The helix 5–
third intracellular loop–helix 6 interface is stabilized by inserting T4
lysozyme (T4L) sequences between residues Leu209(5.70) and
Ala221(6.23). T4L fusion removed the ﬂexible ICL3, increased the
thermostability of the receptor and provided intermolecular contacts
required for crystallization.This engineered receptor construct was expressed in Sf9 insect
cells using a baculovirus vector. Rawmembraneswere separated from
soluble protein by extensive high salt washing, the membranes were
solubilized in dodecyl maltoside, and the engineered receptor puriﬁed
via the 6-His tag using TALON/Co2+/NTA-matrix afﬁnity chromatog-
raphy. The receptor was stabilized throughout the puriﬁcation
process by maintaining high-concentrations of sodium chloride, and
including cholesterol hemisuccinate and the non-speciﬁc, low afﬁnity
antagonist theophylline. Theophylline was exchanged to ZM241385
in the last puriﬁcation step and the puriﬁed receptor:ZM241385
complex was reconstituted into a mono-olein:cholesterol mixture.
Crystallization occurred at relatively low pH (b6) in the presence of
Li2SO4 and ∼30% PEG400 as precipitant. Final diffraction data from 13
crystals was merged to obtain a complete data set at 2.6 Å resolution,
and a number of crystals diffracted beyond 1.8 Å resolution. Excellent
electron density was observed for the 7-transmembrane domain and
T4 lysozyme. The residues Met1-Pro2, Gln148-Ser156 and Glu311-
Ala316 were not modeled.
5.2. Extracellular domains
The extracellular loops of the adenosine A2A receptor form a
funnel-like domain that allows open access to the ligand binding
cavity (Fig. 1B). The electrostatic surface distribution is more even
when compared to β-adrenoceptors, where the negatively charged
binding cleft is very prominent. The binding cleft is primarily formed
by ECL2 and assumes a random coil structure. The electron density is
missing for the amino acids [Gln148(4.69)-Ser156(4.77)] that forms
the tip of the extracellular region. In the adenosine A2A receptor
model, the end of ECL2 contains a very short alpha helical segment
that forms a critical aromatic π-stacking interaction between Phe168
(5.29) and bound ligand (Fig. 1B). The coil structure is held together
by four disulﬁde bridges [71(2.69):159(5.20), 74(3.22):146(4.67) 77
(3.25):166(5.27) and 259(6.61):262(6.64)] (Fig. 2B), the ﬁrst three of
which are unique to the adenosine A2A receptor structure. The human
adenosine A1 and A2B receptors have the corresponding primary
sequence for all four disulﬁde bridges and may also form a coil
stabilized by these disulﬁdes, but the adenosine A3 receptor only has
the pair that are conserved among the family A GPCRs (Fig. 2).
5.3. Antagonist binding pocket
The prototypical adenosine receptor antagonist ZM241385 binds
to the engineered adenosine A2A receptor in an extended conforma-
tion perpendicular to the plane of the membrane bilayer (Fig. 1). This
orientation is very different from the retinal:rhodopsin and the beta-
blockers:β-adrenoceptor structures in which ligands bind parallel to
the plasma membrane. The bicyclic trizolotriazine (BCT) core of
ZM241385 is located in themiddle of the binding cavity, the furan ring
is in the lower part of the binding cavity, and the 4-hydroxypheny-
lethyl (4-HFE) substituent is in the upper part of the binding cavity,
closer to the extracellular space (Fig. 1B).
The BCT core unit forms a number of stabilizing interactions with
residues in the binding cavity. The exocyclic nitrogen of BCT core unit
makes two polar interactions with the conserved Asn253(6.55) and
Glu169(5.30) residues. These polar interactions are important for
designing adenosine A2A receptor antagonists because in adenosine A3
receptor, a valine residue takes the place of Glu169(5.30), eliminating
this stabilizing interaction and potentially contributing to the low
binding afﬁnity of ZM241385 for the adenosine A3 receptor. The BCT
core unit makes a strong hydrophobic π-stacking interaction with
conserved Phe168(5.29), and a hydrophobic interaction with Ile274
(7.39). The BCT core unit makes also several hydrogen bond
interactions (directly or indirectly) with crystallographic water
molecules (#559, #567, #550 and #522) in the binding cavity
(Fig. 1B).
Fig. 3. Structural details of key regions of the human adenosine A2A receptor bound to the antagonist ZM241385. A. Polar interactions between internal water molecules and either
receptor residues or ZM241385. Water molecules are shown as blue dots, interacting side chains as white sticks and bound ZM241385 as a pink stick model. Water molecules #519,
#559 and #567 directly interacts with antagonist ZM241385. B. Interactions between the DRYmotif located in helix 3 and the second intracellular loop. In the adenosine A2A receptor
structure the DRYmotif does not form the classical “ionic lock” between helixes 3 and 6, but instead Arg102(3.50) interacts with Asp101(3.49) stabilizing its deprotonated state that
in turn interacts with Thr41(2.39) of helix two and Tyr112(3.60) of the second intracellular loop. The membrane boundary is indicated as blue dotted line. C. Interactions between
three Arg residues [Arg293(7.58), Arg296(8.47)] and Arg300(8.51)] of helix 8 and sulfate #408 ion. The Arg to Ala mutations disrupt the receptor interactions with Calmodulin [31].
The membrane boundary is indicated as blue dotted line.
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1240 H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244The furan ring is buried deeply in the binding cavity and forms
several hydrophobic interactions [Leu85(3.33), Met177(5.38), Leu249
(6.51), Trp246(6.48) and His250(6.52)] and one polar [Asn253(6.55)]
interaction. The furan ring interactions may directly and indirectly
restrict the movement of the “toggle switch” Trp246(6.48). The
rotamer switch of this residue and the nearby aromatic residues [in
the CW(6.48)XP(6.50)aa sequence] are predicted to be coupled
during activation [25,26]. ZM241385 has a 14 Å2 contact area with
Trp246(6.48) compared to 32 Å2 in the rhodopsin:retinal (inactive)
structure and 0 Å2 in the β2-adrenoceptor:carazolol (reduced basal
activity; apo-β2-adrenoceptor have high basal activity ca. 50%)
structure.
The 4-HFE moiety faces the solvent and makes hydrophobic
interactions with His264(6.66), Leu267(7.32) and Met270(7.35), as
well as a hydrogen bond with crystallographic water molecule #519
(Figs. 2 and 3). The 4-HFE moiety has relatively high crystallographic
temperature factors indicating a larger structural ﬂexibility in this part
of the ZM241385 molecule. Correspondingly, larger substitutions are
tolerated in this part of the ZM241385 pharmacophore.
Several key interactions involved in ZM241385 and other
antagonist binding to the adenosine A2A receptor were recognized
by mutagenesis and binding studies prior to the solution of the crystal
structure (Table 4), including Glu169(5.30), His250(6.52), Asn253
(6.55) and Ile(7.39). ZM241385 makes several interaction that had
not been characterized before, including critical BTC core interactions
with Phe168(5.29) and Leu249(6.51). We have started systematic
mutagenesis of the binding cavity residues to further validate their
roles in ligand binding. Thus far we have validated the critical roles of
Phe168(5.29), Leu249(6.51) and Met177(5.38) for ZM241385 and
agonists such as NECA/CGS15943. Our data suggest that the BCT core,
and the heterocyclic scaffolds generally found in both adenosine
receptor agonists and antagonists, interact with the same core group
of residues in the receptor [27]. We speculate that the selectivity of
ZM241385 for adenosine A2A receptor over adenosine A2B is probably
due to very small sequence variations in the residues of the binding
cavity (positions 6.51 and 7.32, for example). The selectivity of
ZM241385 for the adenosine A2A receptor over the adenosine A3
receptor subtype is much clearer and most likely caused by
differences at positions 6.30, 6.52 and 7.32. Mutagenesis studies
provide evidence that there are several residues that inﬂuence ligand
binding but are not in direct contact (within 5 Å) or close vicinity to
ZM241385 in the crystal structure. We speculate based on in silico
molecular modeling that some of these residues, such as Thr88(3.36),
Phe180(5.41), Asn181(5.48, Phe182(5.34), Ser277(7.42), His278
(7.43) and Ser281(7.46), might interact with small molecule agonists
such as NECA and CGS15943. Most interestingly, the adenosine A2A
receptors have an ordered water cluster (waters #501, #514, #522,
#528 and #567) in the binding cavity (Fig. 3). This water cluster
makes interactions with some of the residues that were identiﬁed as a
“binding residues” prior to the antagonist-bound x-ray structure but
are not in direct contact with or in the vicinity of (5 Å) ZM241385
(Table 4 and Fig. 3). The presence of these waters raises several
important questions: What is the role of these waters for antagonist
selectivity and agonist binding? Do these waters deﬁne the allosteric
modulation site? Are these ordered waters speciﬁc for ZM241385
binding? How to handle these waters during receptor modeling, in
silico screening and drug design?
The adenosine A2A receptor:ZM241385 complex structure was
also used for conducting in silico drug screening with validation of
“hits” through in vivo ligand binding and G protein activation [28].
Over 4,000,000 commercially available lead compounds were com-
putationally docked to the adenosine A2A receptor structure. Themain
interaction residues and waters near ZM241385 were used to deﬁne
and optimize the binding cavity prior docking. Based on the docking
results, 56 chemically diverse top lead compounds were tested for
activity using radioligand binding and G protein functionality. Out ofthe 56 compounds tested, 23 showed activity in the micromolar to
nanomolar range. All compounds were veriﬁed as antagonists and a
limited number displayed subtype selectivity. These compound are
relatively small (b500 Da) and are derivitazable, making them
excellent starting points for drug discovery and development. Very
similar results were obtained by Kobilka and co-workers using β2-
adrenoceptor as a template structure [29]. The identiﬁcation of only
antagonists and not agonists by the screenmight imply that either the
chemical collections are biased towards inactivating compounds or
that the agonist-bound receptor structure truly differs from the
inactivated structures.
5.4. Intracellular domains, carboxy terminal domain and co-factors
The intracellular domain that mediates G protein binding and
signaling is perturbed in the adenosine A2A receptor structure by
insertion of T4 lysozyme and truncation of the carboxy terminal
domain, both of which were necessary for highly ordered crystal
formation. The same is true for β2-adrenoceptors (with T4 lysozyme
and antibody complex) and β1-adrenoceptor (truncations and
receptor mutations). Nevertheless, there are still features of interest
to note. The role of the ICL2 and the DRY motifs has already been
discussed above (section 4.2) (Fig. 3B). Another interesting feature is
the extension of helix 6. Both the adenosine A2A receptor and squid
rhodopsin structures have an extended helix 6 compared to the other
GPCR structures. In the case of the adenosine A2A receptor, this might
be an artifact caused by T4 lysozyme. The lysozyme tilting is different
between adenosine A2A:ZM241385, β2-adrenoceptor:carazolol and
β2-adrenoceptor:timolol receptor structures, although the insertion
sequences are overall quite similar, and identical in the case of β2-
adrenoceptors. In the case of squid rhodopsin, the extension might
have a role in Gαq protein coupling speciﬁcity vs. bovine rhodopsin G
protein-transducin speciﬁcity.
Removal of the carboxy terminus of the adenosine A2A receptor
improved receptor behaviour (such as aggregation, stability and
concentration dependent solubility) in detergent micelles. The
truncated portion potentially contains long amino acid sequences
(about 96 aa) that may lack three-dimensional structure in the
absence of accessory/regulatory proteins. Fascinatingly, it has been
shown that the carboxy terminus of the adenosine A2A receptor is
responsible for G protein-independent signal transduction by PDZ-
like and PDZ-independent scaffold proteins. (This is extensively
reviewed by Dr. M. Freissmuth and co-workers in the later part of this
issue.) It has been also demonstrated in many studies that the carboxy
terminus of the adenosine A2A receptor interacts with alpha-actinin
(type 2), dopamine receptors (types 2 and 3), glutamate mGlu5
receptors and many other regulatory proteins such as NECAB2 (N-
terminal EF-hand calcium binding protein 2), ARNO (ARF-nucleotide
binding site opener), TRAX (translin-associated factor X) and
calmodulin [30]. Interestingly, arginine residues in helix 8 are
believed to contribute to these protein-protein interactions, and
arginine residues in helix 8, Arg293(7.58), Arg296(8.47) and Arg300
(8.51), coordinate a SO4 ion (#408) in the adenosine A2A receptor:
ZM241385 complex structure, raising the possibility that the
antagonist's inactivating/allosteric effects in cytosolic site may be
mediated in part through binding of these arginines. These same
arginines are also shown to interact with the Ca2+-controlled protein
calmodulin [31].
Five lipid molecules were bound to the solved adenosine A2A
receptor structure (Fig. 4) and modeled as stearic acid [24]. The
electron density maps did not support modeling of cholesterol
molecules at this receptorwhereas in high resolutionβ2-adrenoceptor
structures cholesterol moieties were clearly evident [32–34]. Based on
the β2-adrenoceptor structures and sequence similarity to rhodopsin-
like GPCRs, a cholesterol consensus motif (CCM) [R/K(4.39–4.40),
W/Y(4.50), I/V/L(4.46), F/Y(2.41)] was proposed. The CCM motif is
Table 4
Analysis of artiﬁcial mutations for the adenosine A2A receptor residues with respect to ligand binding properties. Table was modiﬁed from [38–41].
Residue Mutation analysis for adenosine A2A receptor ligands Ligand Reference
Mutation Antagonist/Agonist Effect on afﬁnity
Glu13 (1.39) Gln Antagonist No effect SCH58261, CGS15943, Theo, XAC [42,43]
Agonist Decrease DPMA, CGS21680, NECA
Val84 (3.32) Leu Antagonist Decreases CGS15943, XAC, DPCPX [44]
Agonist No effect DPMA, NECA, IB-MECA [44]
Thr88 (3.36) Asp, Glu Antagonist No effect CGS15943 [39]
Agonist No binding NECA [39]
Ala, Ser, Arg Antagonist Decreases CGS15943, ZM241385 [45]
Agonist Decreases CADO, DPMA, NECA, CGS21680 [45]
Gln89 (3.37) Ala, Asp Antagonist Increases SCH58261, CGS15943, XAC, ZM241385 [39,45]
Agonist Increases CADO, DPMA, NECA, R-PIA, IB-MECA, ADAC [39,45]
Ser90 (3.38) Ala Antagonist No effect SCH58261, CGS15943, XAC, ZM241385 [45]
Agonist Increases CADO, DPMA, NECA, R-PIA, IB-MECA, ADAC [45]
Ser91 (3.39) Ala Antagonist No effect SCH58261, CGS15943, XAC, ZM241385 [45]
Agonist No effect CADO, DPMA, NECA, R-PIA, IB-MECA, ADAC [45]
Glu151 (4.72) Ala, Asp, Gln Antagonist No binding XAC [46]
Agonist No binding CGS21680 [46]
Glu161 (5.22) Ala Antagonist Increases CGS15243, XAC [46]
Agonist No effect CADO, DPMA, R-PIA, IB-MACA, NECA [46]
Glu169 (5.30) Ala Antagonist No binding XAC [46]
Agonist No binding CGS21680 [46]
Gln Antagonist No effect XAC [46]
Agonist CADO and NECA, increases,
for other minor decreases
CADO, DPMA, R-PIA, IB-MECA, NECA [46]
Asp170 (5.31) Lys Antagonist No effect XAC [46]
Agonist No effect CGS21680 [46]
Pro173 (5.34) Arg Antagonist No effect XAC [46]
Agonist No effect CGS21680 [46]
Phe180 (5.41) Ala Antagonist No effect CGS15943, XAC [47]
Agonist No effect DPMA, NECA [47]
Asn181 (5.42) Ser Antagonist No effect CGS15943, XAC [47]
Agonist No effect CADO, DPMA, NECA, R-PIA [47]
Phe182 (5.43) Ala Antagonist No binding CGS15943, XAC [47]
Agonist No binding CGS21680 [40]
Tyr, Trp Antagonist No effect CGS15943, XAC [47]
Agonist Decreases CADO, DPMA, NECA, R-PIA [47]
His250 (6.52) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
His250 (6.52) Phe, Tyr, Asn Antagonist No effect CGS15943, XAC [44,47]
Phe, Tyr Agonist Decreases CADO, DPMA, NECA, R-PIA [47]
Asn Agonist Minor increase DPMA, NECA, IB-MECA [44]
Asn 253 (6.55) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
Cys254 (6.56) Ala Antagonist No effect XAC [47]
Agonist No effect DPMA, NECA [47]
Phe257 (6.59) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
Cys262 (6.64) Gly Antagonist No effect XAC [46]
Agonist No effect CGS21680 [46]
Ile274 (7.39) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
Ser277 (7.42) Asn, Thr, Ala, Cys Antagonist No effect SCH58261, CGS15943, XAC, ZM241385 [45,47]
Ala Agonist No effect CGS21680, CADO, DPMA, NECA, R-PIA, IB-MECA [40]
Cys Agonist Decreases CADO, DPMA, NECA, R-PIA, IB-MECA, ADEC [45]
Glu Antagonist No effect CGS15943 [39]
Glu, Asn, Thr Agonist No effect CADO, DPMA, NECA, R-PIA, IB-MECA [39,47]
His278 (7.43) Asp, Glu Antagonist No effect CGS15943 [39]
Asp, Glu Agonist No effect NECA [39]
His278 (7.43) Tyr Antagonist Decrease SCH58261, CGS15943, Theo, XAC [48]
Agonist Decrease DPMA, CGS21680, CPA, NECA [48]
His278 (7.43) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
Ser281 (7.46) Ala Antagonist No binding XAC [47]
Agonist No binding CGS21680 [47]
Ser281 (7.46) Thr Antagonist Increase for XAC XAC, CGS159261 [47]
Agonist Increases CADO, DPMA, NECA, R-PIA, IB-MECA, ADAC [47]
Ser281 (7.46) Asn Antagonist Decrease SCH58261, CGS15943, XAC, ZM241385 [45]
Agonist Decrease SCH58261, CGS15943, XAC, ZM241385 [45]
1241H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244present in 21% of rhodopsin-like GPCRs. The motif speciﬁcity for
cholesterol and other lipids/steroids and its pharmacological signif-
icance needs to be further veriﬁed by mutagenesis and functional
studies [35–37].Steroids/lipids, protein modulators and allosteric compounds
might offer opportunities for the design of novel drugs that act by
binding at locations other than orthosteric ligand binding site,
potentially overcoming subtype selectivity and cross-reactivity
Fig. 4. Lipid binding to the human adenosine A2A receptor. Phospholipids (#402–406) bound to the receptor are shown as ball-and-stick models. Surrounding solvent accessible area
and receptor residues or other phospholipid molecules contributing to speciﬁc phospholipid binding are shown in smaller boxes surrounding the receptor (middle), and two
symmetry related molecules shown in blue and brown. The unit cell is indicated as a purple line.
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1243H. Piirainen et al. / Biochimica et Biophysica Acta 1808 (2011) 1233–1244problems associated with compounds that target the highly con-
served orthosteric ligand binding site.
6. Concluding remarks
The crystallographic model of the human adenosine A2A receptor
with bound antagonist ZM241385 provides new insight from which a
number of previous binding and functional studies can be re-
examined and new studies conceptualized. Nevertheless, like any
other scientiﬁc journey, the crystallographic model of the adenosine
receptor and its counterparts the β-adrenoceptor and rhodopsin/
opsin have raised more questions than answers. Further research
must be targeted to answer these questions: What is the molecular
mechanism of ligand selectivity between adenosine receptor subtypes
or between β-adrenoceptor subtypes? How different is the agonist-
bound state(s) from the antagonist-bound state? Are these states
conformationally different and stable or do they merely alter the
binding kinetics of the receptor with its intracellular binding partners,
and their different populations? There are also more demanding
questions around the corner such as the activation mechanism and
the receptor:agonist:G protein complexes. Based on several confer-
ence presentations and public web-sites this will be an exciting and
interesting year for new GPCRs structures; several new GPCRs
structures have been solved but not yet deposited, including new β-
adrenoceptors and adenosine receptor complexes, the chemokine
CXCR4 receptor, the dopamine D3 receptor and the Sphingosine-1-
phosphate S1P1 receptor (http://cmpd.scripps.edu; http://www.
receptos.com; Stevens, unpublished). It is our hope that some of
these structures might answer some of these questions.
The recent and new crystallographic models with various muta-
tions, fusions and truncations may easily lead to the “drunks under the
lamp-post" problem – “you know the keys are not there but the light is
bright so that is where you look for them". The static crystallographic
models need to be complemented with biophysical, biochemical and
pharmacological approaches to fully appreciate the dynamic nature of
heptahelical receptors and their signaling partners.
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